|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ChiCTR |
|
Last refreshed on:
|
12 August 2024 |
|
Main ID: |
ChiCTR2100050481 |
|
Date of registration:
|
2021-08-27 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Clinical study of liquid biopsy in membranous nephropathy based on urine exosomal proteome detection
|
|
Scientific title:
|
Clinical study of liquid biopsy in membranous nephropathy based on urine exosomal proteome detection |
|
Date of first enrolment:
|
2021-09-01 |
|
Target sample size:
|
Target condition:100;Difficult condition:200 |
|
Recruitment status: |
Recruiting |
|
URL:
|
https://www.chictr.org.cn/showproj.html?proj=132711 |
|
Study type:
|
Diagnostic test |
|
Study design:
|
Sequential
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
China
| | | | | | | |
|
Contacts
|
|
Name:
|
Cai Yanling
|
|
Address:
|
3002 Sun'gang Road West, Futian District, Shenzhen, Guangdong
|
|
Telephone:
|
+86 13530802052 |
|
Email:
|
caiyanling@secretech.com |
|
Affiliation:
|
Shenzhen Second People's Hospital |
|
|
Name:
|
Cai Yanling
|
|
Address:
|
3002 Sun'gang Road West, Futian District, Shenzhen, Guangdong
|
|
Telephone:
|
+86 13530802052 |
|
Email:
|
caiyanling@secretech.com |
|
Affiliation:
|
Shenzhen Second People's Hospital |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria: 1. Plan a kidney biopsy to confirm the pathological type of kidney disease;
2. Sign the informed consent;
3. Aged over 18 years;
4. Have not undergone any invasive testing or treatment intervention.
Exclusion criteria: 1. Combined with infectious diseases such as hepatitis B, hepatitis C, HIV;
2. Combined with cardiovascular and cerebrovascular diseases, tumors and other diseases;
3. Patients with severe infectious diseases;
4. Pregnant and lactating patients;
5. Patients with severely impaired immune response (such as hypogammaglobulinemia, severe CD4 or CD8 cell count reduction);
6. Other conditions deemed inappropriate by other clinicians to participate in this study.
Age minimum:
18
Age maximum:
90
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
membranous nephropathy
|
|
Intervention(s)
|
|
Gold Standard:kidney biopsy;Index test:types and amounts of proteins expressed in exosomes;
|
|
Primary Outcome(s)
|
|
exosomal protein CD26;;;;AUC of ROC;
|
|
Source(s) of Monetary Support
|
|
Hospital-level clinical research of Shenzhen Second People's Hospital
|
|
Ethics review
|
Status: Approved
Approval date: 01/06/2021
Contact:
Xie Ni
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|